ISIS 301012 parenteral: Interim Phase II data

Additional data from an ongoing, double-blind, placebo-controlled Phase II trial showed that 300 mg of weekly ISIS

Read the full 174 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE